Mode
Text Size
Log in / Sign up

Multimodal laboratory diagnostics improve detection of biofilm-encased pathogens and polymicrobial infections in bone and joint infectionsNew Laboratory Tools Improve Diagnosis of Bone and Joint Infections

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider multimodal panels including synovial fluid biomarkers and molecular assays for improved detection of complex BJIs.

This narrative review evaluates the current landscape of laboratory diagnostics for bone and joint infections (BJIs), including periprosthetic joint infection, fracture-related infection, and osteomyelitis. The authors synthesize evidence on various diagnostic modalities to improve identification of pathogens in complex clinical scenarios.

The review highlights that while serum inflammatory markers are valuable for initial screening, they are limited by susceptibility to aseptic inflammatory confounders and are not suitable for standalone confirmation. In contrast, synovial fluid biomarkers such as calprotectin and alpha-defensin offer high diagnostic specificity. Furthermore, tissue sampling with sonication is noted to substantially enhance the recovery of occult biofilm-encased pathogens. Molecular assays, including multiplex PCR and shotgun metagenomic sequencing, expand detection capabilities for culture-negative, low-virulence, and polymicrobial infections.

The authors note limitations such as a lack of global standardization for disease definitions and the need for robust external validation of predictive models. The clinical relevance lies in the shift toward multimodal, culture-independent assay panels and AI-assisted risk stratification. Because this is a narrative review, results reflect current evidence synthesis rather than primary trial data.

How this fits prior evidence

This review addresses gaps in the management of bone and joint infections by detailing advanced diagnostic tools for complex cases. It complements existing coverage on periprosthetic joint infection (PJI) and osteomyelitis by providing specific laboratory techniques to identify pathogens, such as those potentially seen in Brucella periprosthetic joint infection or skull-base osteomyelitis where standard cultures may fail.

Identifying the cause of bone and joint infections, such as those near implants or in bones, can be difficult with standard methods. This review looked at different laboratory tools used to find these infections, including blood tests, fluid markers, and advanced molecular testing.

Researchers found that while blood tests are helpful for initial screening, they can sometimes be confused by other types of inflammation. In contrast, specific biomarkers in joint fluid, like calprotectin and alpha-defensin, showed high accuracy in identifying infection sites. Additionally, using a technique called sonication on tissue samples helped doctors find bacteria hidden inside biofilms that standard tests often miss.

New molecular tools, such as multiplex PCR and metagenomic sequencing, also expanded the ability to detect infections that do not grow in traditional cultures. Because this is a narrative review of current laboratory techniques rather than a clinical trial, these findings represent the current state of science. Patients should talk to their doctors about how these advanced diagnostic tools might be used in their specific care plans.

What this means for you:
Advanced molecular tests and tissue processing can help identify infections that traditional cultures may miss.

Common questions

How do these new tests differ from standard blood tests?

Standard serum markers are useful for initial screening but can be affected by other types of inflammation. In contrast, synovial fluid biomarkers like calprotectin and alpha-defensin provide much higher specificity for identifying the actual infection microenvironment.

What is sonication and how does it help with infections?

Sonication is a method used during tissue sampling. It significantly improves the recovery of pathogens that are hidden inside biofilms, which are often missed by traditional diagnostic methods.

Can these new tests find infections that don't grow in a lab?

Yes, molecular assays such as multiplex PCR and metagenomic sequencing expand the toolkit. They help detect culture-negative, low-virulence, and polymicrobial infections that traditional methods might not catch.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Bone and joint infections (BJIs), including periprosthetic joint infection (PJI), fracture-related infection (FRI), and osteomyelitis, present persistent diagnostic challenges driven by biofilm formation and a high incidence of culture-negative cases. Traditional diagnostic modalities relying on peripheral serum markers and conventional cultures are often limited by insufficient specificity or prolonged turnaround times. This narrative review critically evaluates recent advances in laboratory diagnosis for bone and joint infections, with particular attention to disease-specific applicability across periprosthetic joint infection, fracture-related infection, native vertebral osteomyelitis, diabetic foot osteomyelitis, and other osteomyelitis-related conditions. Current evidence indicates that while traditional serum inflammatory markers are valuable for initial screening, their susceptibility to aseptic inflammatory confounders precludes standalone diagnostic confirmation. In contrast, localized sampling demonstrates significant superiority: novel synovial fluid biomarkers, notably calprotectin and alpha-defensin, accurately reflect the infection microenvironment and offer exceptional diagnostic specificity. At the tissue level, the integration of multiple deep-tissue sampling with preprocessing techniques like sonication has substantially enhanced the recovery of occult biofilm-encased pathogens. Furthermore, targeted and untargeted molecular assays, including multiplex PCR panels, broad-range bacterial PCR, amplicon-based sequencing, and untargeted shotgun metagenomic sequencing, have expanded the diagnostic toolkit for culture-negative, low-virulence, and polymicrobial infections. The diagnostic framework for BJIs has decisively shifted from the pursuit of a solitary “silver bullet” marker toward multimodal, culture-independent assay panels and artificial intelligence-assisted risk stratification algorithms. Future clinical breakthroughs will depend heavily on the global standardization of disease definitions, robust external validation of predictive models, and the seamless integration of advanced laboratory techniques into multidisciplinary team (MDT) workflows.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.